Following in the footsteps of radiology, its brother in imaging analysis arms, digital pathology has recently become a popular canvas for artificial intelligence applications.
Startups like Ibex, previous Fierce 15 honoree Paige, and current Fierce 15 winner PathAI have racked up a handful of regulatory approvals and hundreds of millions in funding for their respective AI-powered biopsy-reading technologies—and now, Verily is looking for a piece of the digital pathology pie.
The Alphabet subsidiary is already working with its sister company, Google Health, to develop AI algorithms that take over the burden of analyzing tissue samples from human pathologists, with an initial focus on assessing prostate cancer tumors.
A new partnership will bring those algorithms to the digital pathology platform that Utah-based Lumea developed to improve objectivity and efficiency in diagnosing, prognosing, and treating prostate cancer.
